Enveric Biosciences (NASDAQ: ENVB) is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids, to provide supportive care for targeted, unmet medical needs, both extending and enhancing patient quality of life.
Enveric Biosciences was incorporated in the state of Delaware on January 11, 2018 and completed its organization, formation, and initial capitalization activities effective as of June 7, 2018
4851 Tamiami Trail N, Suite 200, Naples, FL 34103
SIC: 2834 – Pharmaceutical Preparations
Enveric Biosciences became a publicly traded company through a tender offer and reverse capitalization on December 23, 2020.
You can purchase shares in the Company through a registered broker-dealer of your choice. You cannot purchase units directly from the Company. For information about investing in stocks, you may want to consult a financial professional to explain to you the risks and suitability when investing.
We do not offer a direct stock purchase or dividend reinvestment program.
Enveric Biosciences does not anticipate paying any cash dividends in the foreseeable future.
Haynes and Boone LLP
Equinity can be reached by telephone at (800) 468-9716.